CSL Limited (ASX:CSL; USOTC:CSLLY) has spent 2025 reminding the market of an awkward truth: even “defensive” healthcare giants can deliver very non-defensive share price swings. After a year dominated by vaccine-market volatility, a reshaped strategy for CSL Seqirus, and investor nerves around China pricing, the stock heads into late December with a familiar question hanging in the air—is CSL Limited stock a bruised blue-chip bargain, or a business still working through its hardest chapter? [1]
As of the latest available pricing data around A$175 (weekend markets closed), CSL is trading much closer to its 52‑week lows than its highs (52‑week range shown around A$168 to A$290 on widely followed market screens). [2]
